| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Assay identifies patients eligible for new ovarian cancer drug
Answers from the Lab
About one-third of patients with recurrent epithelial ovarian cancer respond to a new treatment. In this test-specific episode of the "Answers From the Lab" podcast, Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' biomarker test (Mayo ID: AFOLR) identifies patients eligible for the new therapy.
"This is a relatively new FDA-approved test, so there are no other options to identify the biomarker," Dr. Shahi says. "That makes it a unique test that can benefit patients."
Immunohistochemistry staining detects the tumor-associated folate receptor alpha antigen, an attractive therapeutic target.
Nearly 70% of patients with epithelial ovarian cancer relapse after primary treatment with chemotherapy and surgery. "By testing for folate receptor expression, we can identify patients with epithelial ovarian cancer who may benefit from receptor-targeted therapy," Dr. Shahi says.
Listen to learn more about Mayo Clinic Laboratories' FOLR1 predictive assay.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
